IDH2 and acute myeloid leukemia: Enasidenib, a targeted IDH2 inhibitor, was the first drug in its class to gain FDA approval based on results from a 2017 phase I/II trial in patients with IDH2 mutant R/R AML wherein about 19.6% of patients achieved a complete remission with a median duration of response of 5.6 months.